156 related articles for article (PubMed ID: 8174802)
1. Partitioning and inactivation of viruses during isolation of albumin and immunoglobulins by cold ethanol fractionation.
Morgenthaler JJ; Omar A
Dev Biol Stand; 1993; 81():185-90. PubMed ID: 8174802
[TBL] [Abstract][Full Text] [Related]
2. [Evaluation of viral safety of a high-purity human factor VIII concentrate submitted to 2 specific virus inactivation treatments (FANDHI)].
Ristol P; Gensana M; Fernández J; Massot M; Biescas H; Darling A; Jorquera JI; Vericat F
Sangre (Barc); 1996 Apr; 41(2):131-6. PubMed ID: 9045353
[TBL] [Abstract][Full Text] [Related]
3. The viral safety of intravenous immune globulin.
Yap PL
Clin Exp Immunol; 1996 May; 104 Suppl 1():35-42. PubMed ID: 8625542
[TBL] [Abstract][Full Text] [Related]
4. Inactivation of virus in intravenous immunoglobulin G using solvent/detergent treatment and pasteurization.
Aghaie A; Pourfatollah AA; Bathaie SZ; Moazzeni SM; Khorsand Mohammad Pour H; Sharifi Z
Hum Antibodies; 2008; 17(3-4):79-84. PubMed ID: 19029665
[TBL] [Abstract][Full Text] [Related]
5. Viral safety of solvent-detergent treated blood products.
Horowitz B; Prince AM; Horowitz MS; Watklevicz C
Dev Biol Stand; 1993; 81():147-61. PubMed ID: 8174797
[TBL] [Abstract][Full Text] [Related]
6. Specific inactivation of viruses which can potentially contaminate blood products.
Horowitz B
Dev Biol Stand; 1991; 75():43-52. PubMed ID: 1794631
[TBL] [Abstract][Full Text] [Related]
7. Viral validation of the manufacturing process of high purity albumin from placentas.
Grandgeorge M; Véron JL
Dev Biol Stand; 1993; 81():237-44. PubMed ID: 8174808
[TBL] [Abstract][Full Text] [Related]
8. Prion-removal capacity of chromatographic and ethanol precipitation steps used in the production of albumin and immunoglobulins.
Thyer J; Unal A; Thomas P; Eaton B; Bhashyam R; Ortenburg J; Uren E; Middleton D; Selleck P; Maher D
Vox Sang; 2006 Nov; 91(4):292-300. PubMed ID: 17105604
[TBL] [Abstract][Full Text] [Related]
9. Virus reduction in an intravenous immunoglobulin by solvent/detergent treatment, ion-exchange chromatography and terminal low pH incubation.
Roberts PL; Dunkerley C; Walker C
Biologicals; 2012 Sep; 40(5):345-52. PubMed ID: 22658506
[TBL] [Abstract][Full Text] [Related]
10. Inactivation of viruses and safety of stable plasma products.
Morgenthaler JJ
Beitr Infusionsther; 1989; 24():33-9. PubMed ID: 2481546
[TBL] [Abstract][Full Text] [Related]
11. Inactivation of HIV-1 and HIV-2 by various manufacturing procedures for human plasma proteins.
Hilfenhaus JW; Gregersen JP; Mehdi S; Volk R
Cancer Detect Prev; 1990; 14(3):369-75. PubMed ID: 2117485
[TBL] [Abstract][Full Text] [Related]
12. Inactivation and elimination of viruses during preparation of human intravenous immunoglobulin.
Uemura Y; Yang YH; Heldebrant CM; Takechi K; Yokoyama K
Vox Sang; 1994; 67(3):246-54. PubMed ID: 7863623
[TBL] [Abstract][Full Text] [Related]
13. Human intravenous immunoglobulin preparation and virus inactivation by pasteurization and solvent detergent treatment.
Chang CE; Eo HG; Lee YS; Chung SK; Shin JS; Lah YK; Park CW; Jung JT; Huh JW; Lee SM
Prep Biochem Biotechnol; 2000 Aug; 30(3):177-97. PubMed ID: 10919559
[TBL] [Abstract][Full Text] [Related]
14. Viral safety of Nanogam, a new 15 nm-filtered liquid immunoglobulin product.
Terpstra FG; Parkkinen J; Tölö H; Koenderman AH; Ter Hart HG; von Bonsdorff L; Törmä E; van Engelenburg FA
Vox Sang; 2006 Jan; 90(1):21-32. PubMed ID: 16359352
[TBL] [Abstract][Full Text] [Related]
15. Validation of removal of human retroviruses.
Marcus-Sekura CJ
Dev Biol Stand; 1991; 75():133-43. PubMed ID: 1794615
[TBL] [Abstract][Full Text] [Related]
16. Assessment of needs for plasma for fractionation in Europe.
Burckhardt JJ
Biologicals; 1999 Dec; 27(4):337-41. PubMed ID: 10686061
[TBL] [Abstract][Full Text] [Related]
17. Inactivation of hepatitis C virus in low pH intravenous immunoglobulin.
Louie RE; Galloway CJ; Dumas ML; Wong MF; Mitra G
Biologicals; 1994 Mar; 22(1):13-9. PubMed ID: 8068309
[TBL] [Abstract][Full Text] [Related]
18. Contribution to safety of immunoglobulin and albumin from virus partitioning and inactivation by cold ethanol fractionation: a data collection from Plasma Protein Therapeutics Association member companies.
Dichtelmüller HO; Biesert L; Fabbrizzi F; Falbo A; Flechsig E; Gröner A; von Hoegen I; Kempf C; Kreil TR; Lee DC; Pölsler G; Roth NJ
Transfusion; 2011 Jul; 51(7):1412-30. PubMed ID: 21251002
[TBL] [Abstract][Full Text] [Related]
19. Potential contribution of mild pepsin treatment at pH4 to the viral safety of human immunoglobulin products.
Reid KG; Cuthbertson B; Jones AD; McIntosh RV
Vox Sang; 1988; 55(2):75-80. PubMed ID: 3142151
[TBL] [Abstract][Full Text] [Related]
20. [Validation of the virus inactivation capacity of a procedure of human plasma albumin purification by chromatography].
Stoltz JF; Geschier C; Rivat C; Sertillanges P; Grandgeorges M; Liautaud J; Regnault V; Dumont L
Ann Pharm Fr; 1993; 51(2):78-93. PubMed ID: 8250488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
